Scan that makes prostate cancer cells glow could cut need for biopsies

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Bell Potter is tipping this exciting ASX healthcare stock to rise 80%

An important clinical trial announcement is good news for this healthcare stock. The post Bell Potter is tipping this exciting ASX healthcare stock to rise 80% appeared first on The Motley Fool ...

Registrational Phase III AMPLIFY trial: Target number of participants achieved

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Alpha Tau Medical Ltd.: Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...
rmdopen.bmj

Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies

Objective To present updated integrated safety analyses of bimekizumab in patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). Methods Safety data pooled from six phase IIb/III ...

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...
CURE

FDA Approves Pylarify TruVu to Expand Prostate Cancer Imaging

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Targeted Oncology

FDA OKs New Piflufolastat F 18 Formulation for Prostate Cancer Imaging

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of PYLARIFY TruVu (piflufolastat F 18) Injection

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...
PharmiWeb

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical ...

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...
Medscape

PSA May Predict Hormone Therapy Benefit Post-Prostatectomy

A meta-analysis seeks to determine if adding hormone therapy to radiotherapy after prostatectomy improves overall survival.